Good morning and welcome to the Neogen Third Quarter fiscal year 2016 Earnings Results Conference. My name is Brendon, and I will be your operator for today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note this conference is being recorded. And I'll now turn it over to Jim Herbert. You may begin sir.

Right Brendon and good morning and welcome to each of you to our regular quarterly conference call for investors and analysts. Today we'll be reporting to you on our third quarter that ended on February 29. As is our normal custom, I will remind you that some of the statements that are made here today could be termed as forward-looking statements, and these forward-looking statements, of course, are subject to risk and uncertainties. Actual results may differ from those that we discuss today. These risks that are associated with our business are covered in part with Company's Form 10-K as filed with the Securities and Exchange Commission. In addition to those of you who are joining us today by live telephone conference, I also welcome those who may be joined by way of simulcast on the World Wide Web. Following comments this morning as usual, we will entertain questions from participants who are joined by the live conference. And I'm joined today by Rick Calk, Neogen's Chief Operating Officer and Steve Quinlan, Neogen's Chief Financial Officer. Earlier today, Neogen issued a press release announcing the results of our third quarter, which ended on February 29, net income for that third quarter increased 12% to $8.3 million or $0.22 per fully diluted share. That's an increase from last year's $7.5 million that equated to $0.20 per share. On a year-to-date basis net income now is at $26.7 million or $0.71 a share compared to $0.55 a share a year ago. Revenues for the third quarter, also increased by 12% to $76.7 million from the previous year's third quarter of approximately $68.4 million. Neogen achieved this new record in revenue despite a shortfall of approximately $1.8 million in revenues due to currency conversions. Year-to-date, our 2016 revenues increased by 13% and now…

Thank you, Jim and welcome to everyone who is listening. Jim has already reported on the overall sales and profit performance for our third quarter and our press release provided additional details related to our overall quarterly results. I will try to provide a bit more detail on the performance of our Food Safety segment for the quarter. As stated in the press, excuse me, as stated in the press release, the negative effects of the currency conversions obscured what was a solid operational performance for Neogen. Going into the quarter, we knew that our Food Safety segment was facing a very difficult comparison with our third quarter of last year as we recorded a 27% increase in the sales of our test kits to detect DON as we responded to significant outbreaks of this mycotoxin in both North America and Europe. To give you a bit of perspective on last year's DON sales spike, this year we recorded a double-digit decrease in sales of DON test kits as overall testing has understandably declined compared to last year. But it's important to note that our DON sales for this quarter are still 11% above what we recorded two years ago. In essence we've established a new higher normal in mycotoxin test kit sales. It’s also important to note that even with that difficult year-over-year comparison we would have recorded a double-digit increase in organic sales for our Food Safety segment if not for the global currency issues, which Steve will describe in greater detail. Our food allergen product line continues to lead the way in revenue increases for our Food Safety diagnostics. This quarter we recorded a 19% increase in the product line led by increases in sales of our gluten and our soy test. The line has also benefited…

Thanks Rick. While we're at a stopping place here, Steve Quinlan, how about talking about, Rick has talked about the highlights of food safety side. Talk some about the highlights of our Animal Safety Group and take a little deeper look at the quarter's financials that I did in my opening comments.

Sure Jim, thank you. The third quarter of fiscal 2016 was somewhat disappointing from an operating perspective as the shift in product mix and continuing currency headwinds negatively impacted our results. The currency issues masked some solid underlying growth, particularly in our international operations, which I'll talk about a little bit, as the currencies in which we operate continue to weaken versus the dollar compared to the same period last year. The Euro for example was down 8% on average compared to last year's third quarter. The Real in Brazil was down 47% for the comparative quarter. The Peso was 21% lower the Pound Sterling was down 6% on average. The negative impact of the stronger dollar on our comparative revenues for the third quarter was about $1.8 million as Jim mentioned and about a 2% impact on the bottom line. In constant currency, our growth was actually 15% versus the 12% growth reported and reported organic growth of 10% would have been 13% and on the Food Safety segment where our international operations report into, the impact was even more pronounced. Their 8% growth would have been 14% and organic growth of 4% would have been 10%. Now the past couple of weeks has seem some weakening of the dollar against these currencies, but we expect continued volatility in world currency markets in the near term. Rick has already discussed some of the key highlights of the growth in the food safety business. So I am going to focus on our international operations in the Animal Safety segment. Neogen Europe had their first quarterly increase of the year in their local currency with revenues up 4% in the pound sterling, primarily the result of revenue growth in the allergen and AccuPoint Sanitation product lines. However revenues declined by 1%…

Yeah thanks David and real quick, about currency conversions that is concerting, but obviously we'll play whatever hand gets dealt to us. Earlier I talked about strategic moves that we had made during the quarter and then some of the impact that it might have had on the earnings line. Unfortunately strategic opportunities don’t always match up with the three months intervals of reporting quarters. We’ve made three acquisitions so far and considered several more during the year, all of which are integral to our growth strategy. However, organizational cost and legal expenses, inventory issues and all-in necessary expert reports and other things that are required to do a good job and due diligence are now required to be expensed at the time that it is spend. Back in the good old days, we could amortize these as part of the purchase price instead of taking a onetime hit in the quarter in which these occurred. Even good acquisitions don’t always start out in a profitable position in the first month they come on board. India is an example of this and it’s one of the two countries that will have the largest middle class population growth in the next two decades and we needed to be there. Taking into account our start-up expense and organizational cost, our Indian operations have not been profitable to this point and are not likely to be profitable for the remainder for the year. However we anticipated that and suggested earlier that at best the Indian operations might breakeven. The acquisition of our Lab M Culture Media business in Central England is another perfect example of part of our strategy that fit well into our need in Europe management team that's based on Scotland. Again this one has taken some management time and that…

Thank you. And we'll now being the question-and-answer session. [Operator Instructions] And from William Blair we have Brian Weinstein online. Please go ahead.

Hi guys. Thanks for taking the question. I thought we could spend some time on the margin structure. Steve, maybe can you bridge us from last year to this year? You gave obviously what the margins were this year and what they were last year, but in terms of the factors that are kind of driving the decrease there, can you help bridge us quantitatively on what those, which each of those factors contributed?

Yes, Brian, without giving super specific, I would say the currency impact was probably close to a $1 million. The product mix was another $1.2 million, somewhere in that range. Those were kind of the two biggest pieces and really when we're talking product mix, it was just that some of our lower margin product lines or pieces of business did really well this quarter and some of the -- Rick alluded to the DON sales that were down. So our Mycotoxin Group which is a higher gross margin product was a little bit -- was down compared to last year. So the lower margin products exploded. The higher margin products just didn't grow as well.

I'd add to that just to interrupt you just a second, as Steve said, something I probably should have covered Brian is when you're sitting in there with the distributer in a country that it costs them prices as much to buy our product as it did a year ago and we're trying to figure out how to stay even. We have to do some things to adjust their price to keep them in the marketplace. The same thing is true with our own sales in Brazil. We've got a sliding scale on some of that product down there that we supply product from here to Brazil and Brazil sells it to the end-user. And in those cases, we slide the price -- the end-user price on that depending upon what the currency ratio is. So that slid a little bit more this month and we sold product a little cheaper than we did this time last year. The same product a little cheaper and now we've structured that and we've been through this before. It's fortunate, unfortunate, not the first time we've seen Peso and Real valuation particularly the Peso seen it occur this long and is hard, but we've seen it before and we'll recover those margins as the local currency adjusts to the dollar. So that has something to do with the impact too.

Do you guys expect that -- you guys have talked about a 20% target obviously from long time on your operating margins and when you're above that and below that you make adjustments to your business. Is 20% still the right way to think about the operating target here?

I think it is, despite where we are now, I think 20% is still a good bogey. So 20% is good bogey. We're a hell of a long ways off today, aren't we.

Yes so when do you think you get back there and what are the things outside of foreign currency that get you to get back there?

Well it's the operating expense. We've got in India and none of these are big losses, but India is losing money and it won't keep losing money. It's showing now we're budgeting, India is being budgeted and it will start making the reasonable return next year and we're gearing up this strong move on what we're doing for genomics with the new lab and it's kind of a little sister to Lincoln and our operations in Ayr, Scotland. They're good there and we will pick up some additional business and instead of bringing samples from England or France and bringing them to the U.S. and doing the work and sending them back again, we'll be able to do a lot of that internally, there in country now which not only will help a little bit on cost wise, but it will help with all of the clearances of USDA that you've got to clear to bring in animals products and it will make us in country and give us an opportunity. We've got a little competition developing over there It will give us an opportunity to be more competitive in those markets. So those things all working together and I tried to point out in my comments all of the things that we've done that I think are really positive for the growth of the company. It's just that sometimes it's kind of hard to match these up to a three-month interval.

Understood. Okay. Thanks guys.

From Stephens Inc., we have Drew Jones on the line. Please go ahead.

Good morning this is actually Garrett on for Drew. Thanks for taking the questions. So first, just talking about the dairy distribution agreement with large manufacturer, is that something where you saw increased penetration in the markets where you're selling or maybe expansion into new markets and then could you talk about the opportunities with that partnership going forward?

Thank you. Good to hear from you. We've identified always that as we looked at animal proteins coming into the marketplace that dairy was a good place to be. We'll never see the dairy business integrated to the extent that chickens and eggs and milk and pork have been, but because it takes more land mass. So there's a lot of opportunities on the dairy side. We do some things all the way back down to -- we've got a major program going for dairy, have a replacement program through our genomics operation where we're actually able to take samples from a week old calf and tell the dairyman which calves he should save as replacements to go back in his herd. And that goes all the way through to the milk parlor where we are one of the two largest suppliers of diagnostic tests on a worldwide basis for the detection of antibiotic residues that would be in milk at the first point of receipt from the farm. And we've got all of the area in between. This was the case where fortunately our reputation had preceded us and this is an international based company that has some distributors here that they were selling some of their milk processing products through and they said, we've got these products and we're not doing as good in distribution as we would like to do. We would like for you to consider taking these over and handling distribution for us. So it's costing us a little bit. Not much, it's costing a little bit of royalty to do that and they've handed over that book of business to us and we'll grow that business, we'll build on it. So it's another opportunity for us to get to the dairyman and this gets us back really back to the dairy farm. We have a focus on all those dairy operations that have more than 500 head of cattle and this kind of fits in the middle of it. So we were pleased to be able to pick that up. I hope that answers your question. It was almost a political answer as long as it took me to answer, but I've been listening to the politicians lately trying to see if I can talk long and say nothing like they do.

I guess and then just a second question on the partnership with Illumina, if you could give us some little bit more detail on where that's going and if you’ve really seen that start to pull through in it at all and thanks.

Yes, no thank you. Both -- that's another good question. Frankly, the Alumina thing has not progressed as fast as I thought it was. The quick background for those that don't know, we have our own bioinformatics that we develop a number of areas and we work with Illumina and to put those our bioinformatics on a chip then we use their chip to be able to run samples to determine the -- run the raw data in order to get our genomics out. The prior year two, we had been buying those chips from Illumina and then running them ourselves or in some cases selling those chips to somebody else to run on an Illumina instrument or it was markets that we couldn’t reach for one reason or another. And Illumina said that they’d really like to sell those chips themselves and we said that’s great but, this is our proprietary genomics, it’s own and so we formed what I think still believe is to good relationship. It’s our genomics and their chip and they’re going to sell them to somebody else and we can dictate who that’s not going to be and they sell them to somebody else and we get essentially some percent of the profits pending upon several things in the factor. So, bottom line if it worked right, it would have not made any difference when compared to the prior year and which we had to grow sales and then add profits. It's not quite kept where it was a year ago. So if I compare to bottom line this year to bottom line last year, it's probably behind a little bit, but a part of that was just getting the Illumina sales force around the world squared away. So, we continue to believe it was a good relationship and will be a good relationship that we can go forward with.

Thanks.

From Janney Montgomery, we have Paul Knight on the line. Please go ahead.

Hi, Jim. Could you talk to based on your experience, how long it takes to get this pricing cost structure put through the system and is it a quarter, is it six months, could you put what you think the timing is on a adjustment of a more normalized margin?

Paul, I'd be quick to do that if you could tell me what's going to happen to the dollar versus the peso and the Real for the next six months. I'll let you, I [emphasize] [ph] and I apologize for that. A big part of it is really, we can't stand by and let -- we've got a competitor that's in Germany that would like to have part of our business that we've got in EU, and make their product there. They make it under EU costs and we make ours under U.S. dollar and ship it over there and they've got -- they can keep their gross margins and they've got an advantage. Well we can't stand by and let them have that. So in some cases we're adjusting prices I mentioned earlier to take that into account and we will have to continue to do that because whether it's our own operations or our strong distributors that have been our partners for years, we can't let them get beat up in the marketplace. So I don't know how much longer we'll have to do that because I don't know what's going to happen to the currency. Steve said we think we can see it stopping a little bit. We're hedging. We didn't talk about our hedging program, but it's beneficial and we probably need to figure out equation to do a little bit more of that to protect us. But that goes to the other -- at the bottom line. So you don't see what happens to hedging as it relates to the operating side or the gross margin certainly of the business. So I guess I don't know what the answer is. We'll play the hand that's dealt us and we're in a strong position. We're generating growth at the top I think pretty good growth at the bottom line matched it. We would like to be doing better. I don't like particular our operating margins, but I talked a little bit about how I think we can get that up. I don't know, but I think we're okay. It's not where I would like to be, but I think this day in time if you take in the currency conversions, if you can grow the top and bottom line at 12% or better each quarter, that's probably okay.

Yeah, and then may be within the side area was sited, I know in your press release and you comments, but what was this big number behind the big growth in rodenticides?

We bought in some new products, some new -- I’m trying to remember now, I think we got six different technical that impact legal dosage for rats and mice in different ways. Some cases they are anti-coagulants and some cases they prevent the synopsis of the nerve system. You keep looking at those because those populations have a little bit of memory I guess. One guy can remember, one of those rats can remember Uncle Harry ate that and died. So I don’t want to eat that anymore. So you got to give him something new to eat, but I think that's helped us. I think we’ve gained against competition. I don’t think there has been any real increase in marketplace and we’ve got a couple of people out there that are in the rodenticide business that have opted not to be their own manufacturer and so we picked up some commercial business OEM kind of contract manufacturing business has been helpful to us and we can make product for somebody else and let them sell it and particularly if they go into marketplace where we don’t reach and we can sell be okay. So it’s not quite the same margin and we talk about margins. It’s not quite the same margin we would have if we sold it direct to the end user, but we still make very respectable margins. So we don’t have the sales, marketing expense attached to it. I don’t know if that answer the question.

Yes, thank you and then lastly, on the tax rate, I guess Steve, we should take it back to a normalized 34%-35% per the May quarter?

It might be just a little better than that, Paul. It might be in the 32%-33% and then kind of normalizing next year in that 35%ish.

Okay. Thank you.

From Craig-Hallum, we have Charles Huff on the line. Please go ahead.

Hi guys thanks for taking my questions. I had a couple more questions on the DNA and GeneSeek business. So the GeneSeek revenues were up 24% in Lincoln. What were the GeneSeek revenues in Europe?

Steve you got that? It's a very good question, Charles. We fold them together for our own internal purposes, but I can't remember what that number was. It's just beginning to get started good over there. It started earlier in the quarter. We begin to move some stuff earlier in the quarter. So I don't know they've got them at their finger tips just haven't got the right finger tips over here.

How about on volume growth for GeneSeek? Do you have a number for that in the quarter?

Yes I can give you a ballpark figure. Last year in our last fiscal year, we did just slightly over one million samples and we’re now at a current run rate, I don’t know exactly what we’ve done on a year-to-date sample wise, but we’re for the last quarter, we were on a run rate to do at least a million and half. So that would say that if we can continue this run rate that would be talking about 2% increase.

Okay.

But some of those are not the same margins. We get a different margin for genomic work that we do for -- if it's looking at a high price pedigree bull that they want everything on compared to trying to decide to help the poultry guys decide which chickens to save for the next generation of stock for poultry breeding but they are all profitable.

Okay. And then I had a question for you on the Mycotoxin and natural toxin allergen line, I think correct me if I’m wrong, but I think in the fourth quarter of fiscal '15, you had a negative 6% growth or so. So you have kind of an easy year-over-year comparison there. How should we be thinking about that line for the fourth quarter? Should kind of blending the two quarters together be -- kind of closer to your long-term Mycotoxin number? Or I know it's bounced around a lot in terms of the crop, the cleanliness of the crop and so forth. But any guess that you could give us on the fourth quarter?

You did and this is a good question. The crop this year was there is five mycotoxins that are of major importance really two that we talk most about. One is Aflatoxin which affects you in the hot, humid weather and dry weather and the other one is DON vomitoxin that affects small grains that happens when you get in cold wet weather in different times of the year. We have to look to it in Northern and Southern Hemisphere, we’re just strong in Brazil. So that helps us from the Southern Hemisphere crop. I would say that this crop in general, the crop is cleaner this year that, the harvest, the one that we just harvested in North America is Northern Hemispheres cleaner than the one last year. So I know there is not going to be lot of carry on there going into the -- as that grain begins to move out of the grain beans, vomitoxin that wheat is a problem, so that could keep us kind of at pace with last year fourth quarter. Our guys have been -- we're doing, where budgets for New Year and they have been doing a lot of forecasting as we've set through those and trying to figure out where this year is going to end up and of course they got to forecast fourth quarter to do that. So, I don’t know. I think Steve you got handle on that number and may be slightly better than last year but not a lot.

That’s probably a good estimate.

Depends on how much of that wheat and where it goes.

Okay. Fair enough. Well, thanks for taking my questions.

No. Thank you for the questions.

And Charles this is Steve, genomics revenue in Europe was essentially flat with last year.

Okay. And you didn't have the Ayr, Scotland facility up and running last year, right?

No, it was not. We were doing some -- we were bringing samples through there and actually doing some sample extraction. So we would have been taking Ayr but regards whatever and extracted in DNA. I've send in a DNA to Lincoln and then the results coming back. So there would have been some revenues generated there, but nothing like what we're doing now.

Okay. Great. Thanks guys.

Thanks Charles.

From ROTH Capital Partners we have Tony Brenner online. Please go ahead.

Thank you. Good morning. Steve, do you have what international sales as a percent of revenues were in the quarter versus a year ago?

We sure do.

It was 33.3% and last year they were 36.4%.

I know that 33.3% could you break out Brazil and Mexico as a portion of that?

Well we've to do a little math Tony, but we can get there.

I know you're capable.

That's one reason. Of course the international was growing. It's not growing as fast as domestic and Tony as you've heard us say before, we think that two thirds at least two thirds of our opportunity lies outside of the U.S. So that's the reason for talking about Lab M in Central England and the reason we're talking about what we're doing with Ayr. That's the reason we're talking about pushing for India. We're really -- I'm excited about India and I think we'll start to turn the screws pretty quick there, but India that market is still pretty undeveloped and we're in the last testing business down and I decided to use that as a springboard to get our…

While Steve is playing with his Abacus, Jim, will you be making additional acquisitions in India short term or this is how it's turning around?

Well, not short term, but we would like to do that. It's kind of in our strategy. India is really lots of countries where we're not very well connected. You can fly back and forth. You can drive back and forth. So probably as we on the Southwest Coast which we think is pretty important is where we selected that because there is a lot of product going export out of there that’s a big export market for a lot of spices. McCormick has a huge operation there and there is some other things there, but if you can’t get out of the Northeast, then it’s hard to get there. So we will use a springboard of some kind whether it's being able to tie up with a strong distributor that gets strong as nobody is stronger right now, is a pure distributor or whether we'll need to use a testing lab. It’s a springboard like we’re doing in the south.

But you don't need to do that in order to turn the corner?

No, no. We will be profitable in what we've got and I think we will see some profitable months here in the next couple months, but it won't be profitable for the year.

Tony, that number is about 15% of the 33%

Do you have first half?

No, no 15% of the 33%.

Oh, of the 33. I've got it.

The strong spot there is distributer sales, still out of the U.K. you should remember that number. I've been through it back and forth for the last week, but I think $16 million $18 million there for distributer sales in the EU. We managed that through Ayr through our Neogen Europe operation because we're sitting right in the middle of the same time zone and we've got a group just a really fine group of sales and marketing people that handle those EU countries. So that can -- and we're going to I mentioned I think in my comments that we wanted to increase our distribution in the EU. We're in every country, but there's a few where we aren't near as strong as we ought to be and yet there's potential there.

Okay. Thank you very much.

Well thank you, Tony.

[Operator Instructions] And from Hilliard Lyons, we have Kurt Kemper on the line. Please go ahead.

Hey guys, thanks for taking my questions. A quick one for Steve. Do you have how much Virbac added to the top line this quarter?

Virbac was pretty minimal, Kurt. We really bought formulations more than active sales.

We've got some inventory. We've got I don't know. I'm going to work with memory, but total revenues that came from that is probably under $2 million as far as the sales and it's -- correct me if I'm wrong Steve, but mostly that was important just because of the registrations of the technical material they had plus some awful good permits. So we've got opportunities to go to U.S. Canada and Mexico with some products that we didn't have before and in particular in Mexico and Central America they needed an extra rodenticide technical or two because they didn't have enough products for rotation. So that will have an impact for us. It was strategic, didn't do a lot for top line, bottom line. Probably did more, hurt the bottom line than it did anything else in the first quarter because we had to expense all of it and put it on board, but it was a good acquisition and we continue to have relationship with Virbac. In fact we produce another product or two for them on an OEM basis, so we're friends.

Okay. And then last question for regarding GeneSeek, are you starting to see some small producers come on board or at least become more interested as cost decrease to them?

Yes and that business is all over, we do business with 11 major beef breeds in the United States. We’ve got exclusive for 10 of the 11 and we share American Angus with another firm. So that's pedigree type stuff package. Where we see the real growth opportunity is in helping producers select the right replacement animals to go into their herds and dairy is pretty important. 50% U.K. is going to be pretty and you’re going to need to save about half of those for replacement. So which half do you save in this genomic test, which is out there somewhere in the range of $25 is pretty easy to run a test on those that you can't look at them phenotypically when she's a week old or even look at her mother and tell whether she's got the right genetics or not. So that is going to grow, I think it’s clearly going to grow. How fast will it grow I think some of it has to do what the male prices are. The beef side it’s growing big on the beef side for the same reasons and as we expand that market, we’ve got a new program that we're putting in place in Brazil. It's going to be really exciting some things that we’re doing down there. That's a different breed of cattle down there than the old cattle. You'll remember what Brahman Cattle look like. They're more like Brahman Cattle than what Black Angus cattle would look like. So the genomics is different. Nobody has really got a handle on that. But that is going to be -- they're going to continue to be one of the important suppliers of beef to the world. So we’re excited. We’ve been down there for the last couple of weeks again working with our people on the genomics side. So we’re excited about where that sits. It’s good, I just don't know how fast it will grow.

Okay. All right, thank you guys.

And from Great Lakes Review, we have David Stratton on the line. Please go ahead.

Hi thanks for taking the call. I just had a quick question regarding the veterinary instruments and the decline. When is that expected to stop? It's been going down over the last I guess quarter and what are the drivers and when will that turn around?

Actually, the vet instruments have been pretty strong this quarter in particular, there was a decline. So they're flat year-to-date, but the first two quarters of the year they were actually up. It's a very strong product line for the company and we see growth going forward for that product line.

Yeah, if you remember back we made three key acquisitions there over the course of the last two or three year's, which make us the King bird of vet instrument manufacturing in the U.S. and the right products and the right distribution system. There are a few products that we make for suppliers. Their vaccines or medications and we may make a product for them that they include and give it away free to their customers. I suspect and I should know this, but I suspect that the decline that we're looking at there might be as a result of not loss of market share but just difference in perhaps some big orders that might have come in for that companion product stuff a year ago compared to where we are now. We're busy. We're adding some new products there. We've got to spent some time this week looking at new instrument products. So to say well how do you how many more ways can you get an animal treated, poured it on the top, stick it down their throat, stick it through a needle. There's still other ways to do that. So it's a fun business and we'll continue to grow it.

All right. And then on the line of new products in general not just veterinary instruments, but can you talk about new products that may be upcoming or products that have been really strong recently?

I can't talk a lot about what's upcoming because all my competitors are listening to this phone call what we talk to you, but we’ll continue to grow on from several places. We’ve talked about what we're doing on the rodenticides and there are some new products coming there. We’ll do some new products on the cleaner and disinfect side. We’ll introduce and I am thinking now back about the biosecurity area on animal safety. We're doing some new things. It’s going to be fun on the insecticide side, which is a part of the biosecurity. Over on the food safety side for diagnostic products, we’ve got several new products that are coming down for diagnostics. They're going to be used for the same purpose, but they’ll either be easier to use or more accurate or cheaper to the end user. So we’ve got 74 people and I’m not sure that even includes all of our engineers that we’ve got Steve while we're on the Primatech side, but we’ve got at least that many and we’re right now in the final focus of what they're going to start up as new products for next year and they think that’s part of our budgeting session tomorrow. So, I’m pretty excited, continue to be pretty excited about there being opportunities for us. As an example somebody has got to do something about GMOs. If you've been listening to that story, do you label all products that have GMO content or do you label those that don’t have them and somebody has got to have a better taste that what we’ve got now. We’re in that market but not -- it’s not a strong market for us, but some of those issues that are coming along are going to invite new products. There will be some new allergens.

Yes I will go ahead, I’m sorry.

No there will be some new allergens. We’ve got -- I don’t know what it is now. Rick 13 or 14 different ones, but we’ve got -- we’ve got two or three more that we don’t have. Somebody wants one separate for cashew. It’s in our tree nut product with somebody wants to make cashew milk for some reasons. So they’ll go back and make one there and we're just -- if somebody wants we're going to try to help them.

All right. Thank you and then I guess one last housekeeping question, do you have your cash flow from operations number for us?

Yes that should have been it was about $7.1 million for the quarter.

All right. Thank you very much.

From Sio Capital, we have Michael Castor on the line. Please go ahead.

Thanks very much. Two financial questions. The first is I think you said you had $182,000 of hedging gains and the operating income or the other operating income line was positive $385. I'm used to seeing that run zero or a little bit negative excluding the FX. So what was the plus $200,000 in there and what will that be on a normal basis, if you exclude all hedging gains? And the second financial question was with the lower tax rate this quarter without one-time or well better way to ask it is just a normal tax rate excluding this year from the benefit what's the tax rate normally going forward?

All right let's do the tax one first. So this quarter, we were able to use some R&D credits and we'll be able to use some more in the fourth quarter that will take our effective rate in the 30%, let's call it 33% effective rate. Going forward, we'll be back to we'll still be getting benefit from R&D, but we won't be getting any past year benefits. So we'll probably be up in the 35.5% somewhere in there 35.5% kind of more our normal rate. Your question about what's in other income, we have royalty income that flows through our other income and what you saw in the press release, there's also interest income in that line item.

Very much.

Not very much, but those are the two pieces of other income that are inside of that number that you can’t see.

So for other, if there were no hedging gains or losses going forward, what would the normal level of that be?

Well for this quarter, the interest income was $120,000, royalty income was somewhere in the, call it $50,000. So excluding anything currency wise. you're somewhere in the $150,000 to $200,000 and those fluctuate obviously. but those are the numbers.

Great. Thank you very much.

Sure.

And we have no further questions at this time. We will now turn it back to Mr. Jim Herbert for final remarks.

Well thanks very much. Thanks for those of you who are on the call and your continuing interest in what we’re doing and we will keep you posted as new developments occur. Have a good week and Spring is here. Thanks.

Ladies and gentlemen, this concludes today’s conference. Thank you for joining. You may now disconnect.